Trial NCT04385199
Publication NCT04385199, Unpublished (2022) (results posted on registry)
Funding: Not reported/unclear
Conflict of interest: *
Methods | |
RCT Blinding: Unblinded | |
Location :
Single center / USA Follow-up duration (days): 28 | |
Inclusion criteria |
|
Exclusion criteria |
|
Interventions | |
Treatment
Convalescent plasma 200 mL single dose IV infusion over 3 hours |
|
Control
Standard care | |
Participants | |
Randomized participants : Convalescent plasma=20 Standard care=10 | |
Characteristics of participants N= 30 Mean age : NR 17 males Severity : Mild: n=0 / Moderate: n=0 / Severe: n=* Critical: n=* Number of vaccinated participants: NR | |
Primary outcome | |
In the register Change in Respiratory Disease Severity [ Time Frame: day 3 post transfusion ] Change in oxygenation as documented by SaO2/FiO2 at 72 hours after infusion | |
In the report NR | |
Documents available |
Protocol Yes. In English Statistical plan NR Data-sharing willing stated in the publication: Not reported |
Risk of bias Overall The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review |
Some concerns |
General comment | This is an unpublished trial whose results have been reported in ClinicalTrials.gov. The trial registry and protocol were used in data extraction and assessment of risk of bias. The trial was registered retrospectively. No important changes were made to primary or secondary outcomes after recruitment start according to the prospective protocol. The trial achieved the target sample size specified in the registry (n=30). |